FrancophonIA/ELRC3.0 huggingface dataset:
English: This decrease in exposure is not considered clinically relevant and therefore, no dose adjustment is recommended.
Croatian: Budući da se to smanjenje izloženosti ne smatra klinički značajnim, ne preporučuje se prilagođavanje doze.
English: Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycaemic effect of metformin was comparable in males and females.
Croatian: Slično tome, u kontroliranim kliničkim ispitivanjima provedenima u bolesnika s dijabetesom tipa 2, antihiperglikemijski učinak metformina bio je usporediv u muškaraca i žena.
English: This causes blood sugar to be removed in your urine.
Croatian: To uzrokuje izlučivanje šećera iz krvi mokraćom.
English: The AUC of ertugliflozin decreased by approximately 13%, and Cmax decreased by approximately 21% compared to subjects with normal hepatic function.
Croatian: AUC ertugliflozina smanjio se za približno 13%, a Cmax za približno 21% u odnosu na ispitanike s normalnom funkcijom jetre.
English: Multiple-dose administration of rifampin (a UGT and CYP inducer) decreases ertugliflozin AUC and Cmax by 39% and 15%, respectively.
Croatian: Primjena višestrukih doza rifampicina (induktora UGT i CYP enzima) smanjuje AUC i Cmax ertugliflozina za 39% odnosno 15%.
English: - Hypersensitivity to the active substances or to any of the excipients listed in section 6.1; - any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis [DKA]); - diabetic pre coma;
Croatian: - Preosjetljivost na djelatne tvari ili neku od pomoćnih tvari navedenih u dijelu 6.1; - bilo koja vrsta akutne metaboličke acidoze (kao što je laktacidoza, dijabetička ketoacidoza
English: At usual clinical doses and dosing schedules of metformin hydrochloride tablets, steadystate plasma concentrations of metformin are reached within 24-48 hours and are generally <1 µg/ml.
Croatian: Pri uobičajenim kliničkim dozama i režimima doziranja tableta metforminklorida, koncentracije metformina u stanju dinamičke ravnoteže u plazmi postižu se unutar 24 - 48 sati i obično iznose < 1 µg/ml.
English: Patients with moderate renal impairment at baseline had larger mean changes that did not return to baseline at Week 26; these changes reversed after treatment discontinuation.
Croatian: Bolesnici koji su na početku ispitivanja imali umjereno oštećenje funkcije bubrega imali su veće srednje vrijednosti promjene, koje se nisu vratile na početnu vrijednost u 26. tjednu; te su se promjene povukle nakon prekida liječenja.
English: If you notice any of the side effects above, contact your doctor as soon as possible.
Croatian: Ako primijetite bilo koju od navedenih nuspojava, obratite se svom liječniku što je prije moguće.
English: Interference with 1,5 anhydroglucitol (1,5-AG) assay Monitoring glycaemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycaemic control in patients taking medicines containing an SGLT2 inhibitor.
Croatian: Utjecaj na test za određivanje vrijednosti 1,5-anhidroglucitola (1,5-AG) Ne preporučuje se praćenje regulacije glikemije testom za određivanje vrijednosti 1,5-AG jer mjerenja nisu pouzdana za ocjenjivanje regulacije glikemije u bolesnika koji uzimaju lijekove koji sadrže inhibitor SGLT2.
English: Regular assessment of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in elderly patients (see section 4.4).
Croatian: Potrebno je redovito kontrolirati funkciju bubrega radi sprječavanja laktacidoze povezane s metforminom, osobito u starijih bolesnika (vidjeti dio 4.4).
English: • Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.
Croatian: • inhibitorima prijenosnika OCT2 (kao što su cimetidin, dolutegravir, ranolazin, trimetoprim, vandetanib, izavukonazol) može smanjiti eliminaciju metformina kroz bubrege i tako povisiti koncentraciju metformina u plazmi,
English: If you stop taking Segluromet
Croatian: Ako prestanete uzimati Segluromet
English: Food decreases the extent of and slightly delays the absorption of metformin, as shown by approximately a 40% lower mean peak plasma concentration (Cmax), a 25% lower area under the plasma concentration versus time curve (AUC), and a 35-minute prolongation of time to peak plasma concentration (Tmax) following administration of a single 850-mg tablet of metformin with food, compared to the same tablet strength administered fasting.
Croatian: Hrana smanjuje i neznatno odgađa apsorpciju metformina, na što ukazuje približno 40% niža vršna koncentracija u plazmi (Cmax), smanjenje područja ispod krivulje koncentracije u plazmi tijekom vremena (AUC) za 25% te produljenje vremena do postizanja vršne koncentracije u plazmi (Tmax) za 35 min nakon primjene jedne tablete metformina od 850 mg s hranom, u odnosu na primjenu tablete iste jačine natašte.
English: In case of conditions that may lead to fluid loss (e.g., gastrointestinal illness), careful monitoring of volume status (e.g., physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving ertugliflozin.
Croatian: U slučaju stanja koja bi mogla dovesti do gubitka tekućine (npr. gastrointestinalna bolest), preporučuje se pažljivo praćenje volumnog statusa (npr. liječnički pregled, mjerenje krvnog tlaka, laboratorijske pretrage, uključujući određivanje hematokrita) i elektrolita u bolesnika koji primaju ertugliflozin.
English: Caution is therefore advised, especially in patients with renal impairment, when these drugs are coadministered with metformin, as metformin plasma concentration may increase.
Croatian: Stoga se preporučuje oprez kada se ti lijekovi primjenjuju istodobno s metforminom, osobito u bolesnika s oštećenjem funkcije bubrega, jer može doći do povećanja koncentracije metformina u plazmi.
English: If you take more Segluromet than you should If you take too much Segluromet, talk to a doctor or pharmacist straight away.
Croatian: Ako uzmete više lijeka Segluromet nego što ste trebali, odmah se obratite liječniku ili ljekarniku.
English: Experience in New York Heart Association (NYHA) class I-II is limited, and there is no experience in clinical studies with ertugliflozin in NYHA class III-IV.
Croatian: New York Heart Association) stupnja I-II je ograničeno, dok nema iskustva iz kliničkih ispitivanja ertugliflozina u bolesnika sa zatajenjem srca NYHA stupnja III-IV.
English: Ertugliflozin was used as monotherapy in one trial and as add-on therapy in two trials (see section 5.1).
Croatian: Ertugliflozin se u jednom ispitivanju primjenjivao kao monoterapija, a u dva kao dodatna terapija (vidjeti dio 5.1).
English: Ertugliflozin does not exhibit time-dependent pharmacokinetics and accumulates in plasma up to 10-40% following multiple dosing.
Croatian: Farmakokinetika ertugliflozina nije ovisna o vremenu, a njegova akumulacija u plazmi nakon višestruke primjene iznosi 10 - 40%.
English: Diabetic ketoacidosis (rare, may affect up to 1 in 1,000 people) These are the signs of diabetic ketoacidosis (see also section “Warnings and precautions”):
Croatian: Dijabetička ketoacidoza (rijetko, može se javiti u do 1 na 1000 osoba) Znakovi dijabetičke ketoacidoze (pogledajte i dio „Upozorenja i mjere opreza“) su:
English: • experience rapid weight loss, feeling sick or being sick, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat, contact a doctor or the nearest hospital straight away.
Croatian: • ako primijetite nagli gubitak tjelesne težine, mučninu ili povraćanje, bol u trbuhu, prekomjernu žeđ, ubrzano i duboko disanje, smetenost, neuobičajenu pospanost ili umor, slatkast zadah, sladak ili metalan okus u ustima ili izmijenjen miris mokraće ili znoja, odmah se obratite liječniku ili otiđite u najbližu bolnicu.
English: When this medicine is used in combination with insulin or medicines that increase insulin release from the pancreas, low blood sugar (hypoglycaemia) can occur.
Croatian: Kada se ovaj lijek koristi u kombinaciji s inzulinom ili lijekovima koji pospješuju oslobađanje inzulina iz gušterače, mogu se javiti niske razine šećera u krvi (hipoglikemija).
English: p 0.001 compared to placebo.
Croatian: p  0,001 u odnosu na placebo.
English: Steady-state is reached after 4 to 6 days of once-daily dosing with ertugliflozin.
Croatian: Stanje dinamičke ravnoteže postiže se nakon 4 do 6 dana primjene ertugliflozina jedanput na dan.
English: Ertugliflozin may increase the risk of hypoglycaemia when used in combination with insulin and/or an insulin secretagogue.
Croatian: Ertugliflozin može povećati rizik od hipoglikemije kada se primjenjuje u kombinaciji s inzulinom i/ili inzulinskim sekretagogom.
English: Because renal function abnormalities can occur after initiating ertugliflozin, and metformin is known to be substantially excreted by the kidneys, Segluromet should be used with caution in the elderly.
Croatian: Budući da nakon uvođenja ertugliflozina mogu nastupiti poremećaji funkcije bubrega, a poznato je da se metformin u značajnoj mjeri izlučuje putem bubrega, Segluromet treba primjenjivati uz oprez u starijih bolesnika.
English: Microscopic changes related to glucosuria and/or calciuria observed only in rodents included dilatation of renal tubules, hypertrophy of zona glomerulosa in adrenal glands (rats), and increased trabecular bone (rats).
Croatian: Mikroskopske promjene povezane s glukozurijom i/ili kalciurijom opažene samo u glodavaca uključivale su proširenje bubrežnih tubula, hipertrofiju sloja zona glomerulosa kore nadbubrežne žlijezde (štakori) i povećanje trabekularne kosti (štakori).
English: In trials with SGLT2 inhibitors, patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections (see section 4.8).
Croatian: U ispitivanjima inhibitora SGLT2, bolesnici s genitalnim gljivičnim infekcijama u anamnezi i neobrezani muškarci imali su veću vjerojatnost razvoja genitalnih gljivičnih infekcija (vidjeti dio 4.8).
English: No studies of metformin pharmacokinetic parameters according to race have been performed.
Croatian: Nisu provedena ispitivanja parametara farmakokinetike metformina s obzirom na rasu.
English: Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared to healthy young subjects.
Croatian: Ograničeni podaci iz kontroliranih farmakokinetičkih ispitivanja metformina provedenih u zdravih starijih ispitanika ukazuju na to da je ukupni klirens metformina iz plazme smanjen, poluvijek produljen, a Cmax povećan u odnosu na zdrave mlađe ispitanike.
English: • blood tests may show changes in the amount of red blood cells in your blood (called haemoglobin)
Croatian: • nalazi krvnih pretraga mogu pokazivati promjene u količini crvenih krvnih stanica u krvi (koje se zovu hemoglobin)
English: Before initiating ertugliflozin/metformin, consider factors in the patient history that may increase the risk for amputation.
Croatian: Prije uvođenja ertugliflozina/metformina, potrebno je uzeti u obzir čimbenike iz bolesnikove anamneze koji bi mogli povećati rizik od amputacije.
English: Temporary interruption of ertugliflozin should be considered when treating pyelonephritis or urosepsis.
Croatian: Potrebno je razmotriti privremeni prekid primjene ertugliflozina tijekom liječenja pijelonefritisa ili urosepse.
English: Effects of ertugliflozin on the pharmacokinetics of other medicinal products Interaction studies conducted in healthy volunteers suggest that ertugliflozin had no clinically relevant effect on the pharmacokinetics of sitagliptin, metformin, and glimepiride.
Croatian: Učinci ertugliflozina na farmakokinetiku drugih lijekova Ispitivanja interakcija provedena u zdravih dobrovoljaca ukazuju na to da ertugliflozin nije imao klinički značajnog učinka na farmakokinetiku sitagliptina, metformina i glimepirida.
English: These increases are not considered to be clinically meaningful.
Croatian: Ta se povećanja ne smatraju klinički značajnima.
English: It is not known if Segluromet passes into breast milk.
Croatian: Nije poznato izlučuje li se Segluromet u majčino mlijeko.
English: Ertugliflozin may add to the diuretic effect of diuretics and may increase the risk of dehydration and hypotension (see section 4.4).
Croatian: Ertugliflozin može pridonijeti diuretičkom učinku diuretika te povećati rizik od dehidracije i hipotenzije (vidjeti dio 4.4).
English: The pharmacokinetics of ertugliflozin are similar in healthy subjects and patients with type 2 diabetes.
Croatian: Farmakokinetika ertugliflozina slična je u zdravih ispitanika i bolesnika s dijabetesom tipa 2.
English: N = 248 N = 247
Croatian: N = 250 N = 248 N = 247
English: • feeling dizzy, light-headed, or weak, especially when you stand up
Croatian: • omaglicu, ošamućenost ili slabost, osobito pri ustajanju, • nesvjesticu.
English: Therefore, Segluromet should not be used during pregnancy.
Croatian: Stoga se Segluromet ne smije primjenjivati tijekom trudnoće.
English: - severe renal failure (GFR less than 30 ml/min), end-stage renal disease (ESRD), or patients on dialysis (see section 4.4); - acute condition with the potential to alter renal function, such as: dehydration, severe infection, shock; - acute or chronic disease that may cause tissue hypoxia, such as: cardiac or respiratory failure, recent myocardial infarction, shock; - hepatic impairment; - acute alcohol intoxication, alcoholism.
Croatian: - dijabetička pretkoma; - teško zatajenje bubrega (GFR manji od 30 ml/min), terminalna faza bubrežne bolesti ili bolesnici na dijalizi (vidjeti dio 4.4); - akutno stanje koje može utjecati na funkciju bubrega, kao što je: dehidracija, teška infekcija, šok; - akutna ili kronična bolest koja može izazvati hipoksiju tkiva, kao što je: zatajenje srca ili disanja, nedavni infarkt miokarda, šok; - oštećenje funkcije jetre; - akutno trovanje alkoholom, alkoholizam.
English: Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1,500 mg/kg/day, respectively.
Croatian: Provedena su dugoročna ispitivanja kancerogenosti na štakorima (primjena tijekom 104 tjedna) i miševima (primjena tijekom 91 tjedna) uz doze koje su iznosile najviše 900 mg/kg na dan odnosno 1500 mg/kg na dan.
English: The impact of UGT inhibitors on the pharmacokinetics of ertugliflozin has not been studied clinically, but potential increase in ertugliflozin exposure due to UGT inhibition is not considered to be clinically relevant.
Croatian: Učinak inhibitora UGT-a na farmakokinetiku ertugliflozina nije klinički ispitan, ali se moguće povećanje izloženosti ertugliflozinu zbog inhibicije UGT-a ne smatra klinički značajnim.
English: With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.
Croatian: Kod liječenja metforminom lučenje inzulina ostaje nepromijenjeno, dok se razine inzulina natašte i cjelodnevni odgovor inzulina u plazmi zapravo mogu smanjiti.
English: If a dose is missed, it should be taken as soon as the patient remembers.
Croatian: Ako bolesnik propusti uzeti dozu lijeka, treba je uzeti čim se sjeti.
English: General introduction
Croatian: Opći uvod
English: In rare instances, phimosis was reported and sometimes circumcision was performed (see section 4.4).
Croatian: U rijetkim je slučajevima prijavljena fimoza te je u nekim slučajevima provedeno obrezivanje (vidjeti dio 4.4).
English: In the pool of placebo-controlled studies, the incidence of adverse events related to volume depletion (dehydration, dizziness postural, presyncope, syncope, hypotension, and orthostatic hypotension) was low (< 2%) and not notably different across the ertugliflozin and placebo groups.
Croatian: Prema objedinjenim podacima iz placebom kontroliranih ispitivanja, incidencija štetnih događaja povezanih s deplecijom volumena (dehidracija, posturalna omaglica, presinkopa, sinkopa, hipotenzija i ortostatska hipotenzija) bila je niska (< 2%) i nije se značajno razlikovala između skupina liječenih ertugliflozinom i onih koje su primale placebo.
English: • if you have uncontrolled diabetes, with, for example, severe hyperglycaemia (high blood glucose), nausea, vomiting, diarrhoea, rapid weight loss, lactic acidosis (see “Risk of lactic acidosis” below) or ketoacidosis.
Croatian: • ako imate nekontroliranu šećernu bolest uz, primjerice, tešku hiperglikemiju (visoka razina glukoze u krvi), mučninu, povraćanje, proljev, brz gubitak tjelesne težine, laktacidozu (pogledajte „Rizik od laktacidoze“ niže) ili ketoacidozu.
English: Ertugliflozin in combination with metformin
Croatian: Ertugliflozin u kombinaciji s metforminom
English: Only 1.5% of the administered dose was excreted as unchanged ertugliflozin in urine and 34% as unchanged ertugliflozin in faeces, which is likely due to biliary excretion of glucuronide metabolites and subsequent hydrolysis to parent.
Croatian: Svega 1,5% primijenjene doze izlučilo se u obliku neizmijenjenog ertugliflozina u mokraću, a 34% u obliku neizmijenjenog ertugliflozina u stolicu, što je vjerojatno posljedica izlučivanja glukuronidnih metabolita u žuč i njihove kasnije hidrolize u ishodišni spoj.
English: Metformin is contraindicated in patients with GFR < 30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3).
Croatian: Metformin je kontraindiciran u bolesnika kojima je GFR < 30 ml/min, a njegovu primjenu treba privremeno obustaviti ako su prisutna stanja koja utječu na funkciju bubrega (vidjeti dio 4.3).
English: Adults with normal renal function (glomerular filtration rate [GFR] ≥ 90 ml/min)
Croatian: Odrasli s urednom funkcijom bubrega (brzina glomerularne filtracije [engl. glomerular filtration rate, GFR] ≥ 90 ml/min)
English: Due to the mechanism of action of ertugliflozin, patients taking Segluromet will test positive for glucose in their urine.
Croatian: Zbog mehanizma djelovanja ertugliflozina, bolesnici koji uzimaju Segluromet imat će pozitivan nalaz testa na glukozu u mokraći.
English: Ertugliflozin did not show any toxicity in healthy subjects at single oral doses up to 300 mg and multiple doses up to 100 mg daily for 2 weeks.
Croatian: Ertugliflozin nije imao toksičnih učinaka u zdravih ispitanika nakon primjene jednokratnih peroralnih doza do 300 mg i višestrukih doza do 100 mg na dan tijekom 2 tjedna.
English: Other risk factors for lactic acidosis are excessive alcohol intake, hepatic insufficiency, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5).
Croatian: Drugi čimbenici rizika za laktacidozu su prekomjerni unos alkohola, insuficijencija jetre, neodgovarajuće kontroliran dijabetes, ketoza, dugotrajno gladovanje i svako stanje povezano s hipoksijom, kao i istodobna primjena lijekova koji mogu uzrokovati laktacidozu (vidjeti dijelove 4.3 i 4.5).
English: Plasma Cmax and AUC of ertugliflozin increase in a dose-proportional manner following single doses from 0.5 mg to 300 mg and following multiple doses from 1 mg to 100 mg.
Croatian: Cmax i AUC ertugliflozina u plazmi povećavaju se proporcionalno dozi nakon primjene pojedinačnih doza od 0,5 mg do 300 mg i nakon višestrukih doza od 1 mg do 100 mg.
English: In the event of an overdose with Segluromet, employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient's clinical status.
Croatian: U slučaju predoziranja lijekom Segluromet potrebno je primijeniti uobičajene potporne mjere (npr. ukloniti neapsorbirani materijal iz probavnog sustava, provoditi kliničko praćenje i uvesti potporno liječenje) u skladu s bolesnikovim kliničkim statusom.
English: The risk of developing lactic acidosis is also increased with uncontrolled diabetes, serious infections, prolonged fasting or alcohol intake, dehydration (see further information below), liver problems and any medical conditions in which a part of the body has a reduced supply of oxygen (such as acute severe heart disease).
Croatian: Rizik od razvoja laktacidoze također je povećan uz nekontroliranu šećernu bolest, ozbiljne infekcije, dugotrajno gladovanje ili uzimanje alkohola, dehidraciju (dodatne informacije pogledajte niže), tegobe s jetrom i sva zdravstvena stanja u kojima dio tijela ima smanjenu opskrbu kisikom (kao što je akutna teška srčana bolest).
English: Across the clinical program for ertugliflozin, ketoacidosis was identified in 3 of 3,409 (0.1%) ertugliflozin-treated patients and 0.0% of comparator-treated patients (see section 4.4).
Croatian: U cjelokupnom programu kliničkih ispitivanja ertugliflozina ketoacidoza je utvrđena u 3 od 3409 (0,1%) bolesnika liječenih ertugliflozinom te 0,0% bolesnika koji su primali usporedni lijek (vidjeti dio 4.4).
English: Alternative methods should be used to monitor glycaemic control.
Croatian: Za praćenje regulacije glikemije treba koristiti druge metode.
English: Ertugliflozin glucuronides had no effect on these isoforms.
Croatian: Glukuronidi ertugliflozina nisu utjecali na te izooblike.
English: Due to its mechanism of action, ertugliflozin induces an osmotic diuresis and increases serum creatinine and decreases eGFR.
Croatian: Zbog svog mehanizma djelovanja, ertugliflozin inducira osmotsku diurezu, povisuje razine kreatinina u serumu i smanjuje eGFR.
English: Before initiating Segluromet, volume status should be assessed and corrected if indicated.
Croatian: Prije uvođenja lijeka Segluromet potrebno je ocijeniti volumni status i po potrebi ga korigirati.
English: Dose-response modelling indicates that ertugliflozin 5 mg and 15 mg result in near maximal urinary glucose excretion (UGE) in patients with type 2 diabetes mellitus, providing 87% and 96% of maximal inhibition, respectively.
Croatian: Model odgovora s obzirom na dozu ukazuje na to da ertugliflozin u dozi od 5 mg odnosno 15 mg dovodi do gotovo maksimalnog izlučivanja glukoze mokraćom (engl. urinary glucose excretion,UGE) u bolesnika s dijabetes mellitusom tipa 2, uzrokujući maksimalnu inhibiciju od 87% odnosno 96%.
English: Metformin is present in human breast milk.
Croatian: Metformin je prisutan u majčinom mlijeku.
English: • in patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetes
Croatian: • u bolesnika koji uzimaju najviše podnošljive doze metformina kao dodatak drugim lijekovima za liječenje dijabetesa
English: Packs of 14, 28, 56, 60, 168, and 180 film-coated tablets in non-perforated blisters and multipacks containing 196 (4 packs of 49) film-coated tablets in non-perforated blisters.
Croatian: Pakiranja od 14, 28, 56, 60, 168 i 180 filmom obloženih tableta u neperforiranim blisterima i višestruka pakiranja koja sadrže 196 (4 pakiranja od 49) filmom obloženih tableta u neperforiranim blisterima.
English: The dosage should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability using the recommended daily dose of 5 mg or 15 mg of ertugliflozin, while not exceeding the maximum recommended daily dose of metformin.
Croatian: Dozu treba individualno prilagoditi prema bolesnikovu postojećem režimu, učinkovitosti i podnošljivosti, koristeći preporučenu dnevnu dozu ertugliflozina od 5 mg ili 15 mg i ne prelazeći pritom najvišu preporučenu dnevnu dozu metformina.
English: These doses are both approximately four times the maximum recommended human daily dose of 2,000 mg based on body surface area comparisons.
Croatian: Obje su te doze približno četiri puta veće od maksimalne preporučene dnevne doze za ljude od 2000 mg (na temelju usporedbi tjelesne površine).